biktarvy Drug Patent Profile

Which patents cover Biktarvy, and what generic alternatives are available?

Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has three hundred and two patent family members in fifty countries.

The generic ingredient in BIKTARVY is bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. Two suppliers are listed for this compound. Additional details are available on the bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Biktarvy

Biktarvy was eligible for patent challenges on February 7, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 8, 2036. This may change due to patent challenges or generic licensing.

There have been sixteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for biktarvy

International Patents:	302
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	44
Drug Prices:	Drug price information for biktarvy
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for biktarvy
What excipients (inactive ingredients) are in biktarvy?	biktarvy excipients list
DailyMed Link:	biktarvy at DailyMed

See drug prices for biktarvy

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for biktarvy

NDA:

210251

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for biktarvy

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gilead Sciences	NA
Brigham and Women's Hospital	NA
Trutag Technologies	NA

See all biktarvy clinical trials

Pharmacology for biktarvy

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for BIKTARVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	30 mg/120 mg/ 15 mg	210251	1	2023-09-28
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	50 mg/200 mg/ 25 mg	210251	3	2022-02-07

US Patents and Regulatory Information for biktarvy

biktarvy is protected by eight US patents and five FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No			Y	Y
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes			Y	Y

Expired US Patents for biktarvy

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018

International Patents for biktarvy

When does loss-of-exclusivity occur for biktarvy?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Cuba

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Mexico

New Zealand

Peru

Philippines

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering biktarvy around the world.

Country	Patent Number	Title	Estimated Expiration
Iceland	2985
Japan	H10147586	ANTIVIRAL ACTIVITY OF 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSIN-1-YL)-1,3-OXATHIOLANE AND ITS PRODUCTION
Costa Rica	20180253
Japan	2021193090	多環式カルバモイルピリドン化合物およびその薬学的用途 (POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE)
Slovakia	279542

Supplementary Protection Certificates for biktarvy

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1301519	300803	Netherlands		PRODUCT NAME: TENOFOVIRALAFENAMIDE OF EEN ZOUT OF SOLVAAT DAARVAN, MET NAME TENOFOVIRALAFENAMIDEFUMARAAT; NATIONAL REGISTRATION NO/DATE: EU/1/15/1061/002 20151123; FIRST REGISTRATION: EU EU/1/15/1061/001 20151123
2822954	C201830044	Spain		PRODUCT NAME: BICTEGRAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR BICTEGRAVIR SODIO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1289; DATE OF AUTHORISATION: 20180621; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1289; DATE OF FIRST AUTHORISATION IN EEA: 20180621
1301519	132016000035069	Italy		PRODUCT NAME: TENOFOVIR ALAFENAMIDE O UN SUO SALE O UN SOLVATO DELLO STESSO, IN PARTICOLARE TENOFOVIR ALAFENAMIDE FUMARATO(GENVOYA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1061, 20151123
2822954	717	Finland
2822954	LUC00083	Luxembourg		PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625

BIKTARVY: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

BIKTARVY (bictegravir, emtricitabine, tenofovir alafenamide) is a fixed-dose combination antiretroviral medication used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Its market performance is characterized by strong sales growth, driven by its efficacy, safety profile, and broad label indications, alongside competitive pressures from both branded and generic alternatives. The financial trajectory of BIKTARVY is directly linked to its patent landscape, market access, and the evolving treatment paradigms in HIV management.

What is BIKTARVY's Current Market Position?

BIKTARVY holds a leading position in the HIV treatment market. Its approval by the U.S. Food and Drug Administration (FDA) in February 2018 and subsequent approvals in other major markets have facilitated widespread adoption. The drug is indicated for treatment-naïve and treatment-experienced adult patients with HIV-1 infection, including those with certain resistance mutations.

Key Market Share Indicators:

• U.S. Market: BIKTARVY has become a cornerstone therapy, often recommended as a first-line treatment option by professional guidelines. Its market share within the single-tablet regimen (STR) segment for HIV treatment has steadily increased.
• Global Market: International markets, including Europe and Japan, also demonstrate strong uptake. Pharmaceutical company Gilead Sciences, the manufacturer of BIKTARVY, has prioritized global commercialization efforts.
• Competitive Landscape: The HIV treatment market is highly competitive. BIKTARVY competes with other STRs such as Triumeq (abacavir, dolutegravir, lamivudine), Dovato (dolutegravir, lamivudine), and Juluca (dolutegravir, rilpivirine), as well as multi-tablet regimens.

What are the Key Efficacy and Safety Advantages Driving BIKTARVY's Adoption?

BIKTARVY's clinical profile is a primary driver of its market success. The combination of bictegravir, an integrase strand transfer inhibitor (INSTI), with emtricitabine and tenofovir alafenamide (nucleoside reverse transcriptase inhibitors, NRTIs), offers a potent and well-tolerated regimen.

Clinical Data Highlights:

• High Efficacy: Clinical trials, such as the EMBRACE and BICSTAR studies, have demonstrated high rates of virologic suppression (HIV-1 RNA < 50 copies/mL) at 48 and 96 weeks of treatment, often exceeding 90% [1].
• Low Barrier to Resistance: Bictegravir has a high genetic barrier to resistance, meaning it is less likely for the virus to develop resistance to the drug compared to some older INSTIs [2].
• Favorable Renal and Bone Profile: Tenofovir alafenamide (TAF), a component of BIKTARVY, has demonstrated a lower incidence of renal and bone adverse events compared to the older tenofovir disoproxil fumarate (TDF) formulation used in other regimens [3]. This is a significant advantage for long-term HIV management.
• Well-Tolerated: BIKTARVY is generally well-tolerated, with common adverse events including nausea, diarrhea, and headache. Serious adverse events are rare.

What is the Patent Landscape for BIKTARVY?

The patent portfolio surrounding BIKTARVY is critical to its commercial exclusivity and future revenue streams. Gilead Sciences has secured multiple patents covering the composition of matter for bictegravir, the fixed-dose combination, manufacturing processes, and specific uses.

Key Patents and Expirations:

• U.S. Composition of Matter Patent for Bictegravir: U.S. Patent No. 8,916,571. This patent, crucial for the active ingredient, is set to expire in 2032 [4].
• U.S. Combination Patent: Patents covering the fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide also exist. These patents, which can extend market exclusivity, typically have expiration dates around the same period or slightly later, often linked to the composition of matter patents.
• Orphan Drug Exclusivity (ODE): BIKTARVY received 7 years of ODE in the U.S. upon its initial approval, which concluded in February 2025. This exclusivity prevents other companies from obtaining FDA approval for a drug for the same orphan indication based on a competitor's data [5].
• Data Exclusivity: In addition to patent protection, regulatory data exclusivity periods provide market protection post-approval.
• Potential for Patent Challenges: As BIKTARVY nears its key patent expiry dates, it becomes a target for Paragraph IV patent certifications by generic manufacturers. These filings initiate a period of potential litigation and Hatch-Waxman challenges, which could lead to earlier generic entry.

Global Patent Status:

Similar patent protection strategies have been employed in other major markets, including Europe, Japan, and Canada, with corresponding expiry dates. The strength and scope of these international patents are vital for Gilead's global revenue.

How is BIKTARVY Performing Financially?

BIKTARVY has been a significant revenue generator for Gilead Sciences since its launch. Its financial performance reflects its strong market adoption and therapeutic positioning.

Revenue Trends:

• 2018: Upon its launch in February 2018, BIKTARVY rapidly gained traction. Its initial sales contributed substantially to Gilead's HIV franchise revenue.
• 2019-2022: Sales continued to grow year-over-year, driven by increasing market share and expanding geographic reach.
  • 2019: Approximately $3.7 billion
  • 2020: Approximately $4.7 billion
  • 2021: Approximately $5.3 billion
  • 2022: Approximately $6.1 billion [6]
• 2023: BIKTARVY reported net product sales of approximately $7.7 billion for the full year 2023, representing a significant year-over-year increase of 26% [7]. This continued robust growth underscores its market dominance.

Factors Influencing Financial Performance:

• Pricing: BIKTARVY is a premium-priced medication reflecting its advanced therapeutic profile and R&D investment. Pricing strategies are influenced by market competition, payer negotiations, and formulary access.
• Volume: The increasing number of patients initiated on BIKTARVY globally is the primary driver of volume growth.
• Geographic Expansion: Successful launches and market penetration in emerging markets contribute to overall sales.
• Contractual Rebates and Discounts: Pharmaceutical companies provide rebates and discounts to payers and pharmacy benefit managers (PBMs) to secure formulary placement. These significantly impact the net revenue received by the manufacturer.

What are the Key Market Access and Reimbursement Considerations?

Market access and reimbursement are crucial for BIKTARVY's sustained commercial success. Navigating diverse healthcare systems and payer landscapes is a complex undertaking.

Payer Landscape:

• Formulary Placement: BIKTARVY generally enjoys favorable formulary placement on most major U.S. and European health insurance plans due to its clinical profile and guideline recommendations.
• Prior Authorization and Step Therapy: While preferred, some payers may still implement prior authorization requirements or step-therapy protocols, demanding that patients try less expensive alternatives before approving BIKTARVY.
• Value-Based Agreements: The HIV treatment market is increasingly exploring value-based agreements, where payment is linked to patient outcomes. This could influence future contracting for BIKTARVY.

Global Reimbursement Strategies:

• Health Technology Assessment (HTA): In many countries, HTA bodies evaluate the cost-effectiveness of new drugs. BIKTARVY's value proposition, supported by clinical trial data and real-world evidence, is key to securing positive reimbursement recommendations.
• Pricing Negotiations: Gilead engages in direct pricing negotiations with national health systems and private payers in each market to establish pricing that reflects therapeutic value and affordability.

What are the Future Growth Drivers and Challenges?

BIKTARVY's future trajectory will be shaped by several growth drivers and potential challenges.

Growth Drivers:

• Continued Guideline Support: As long as BIKTARVY remains a preferred option in major HIV treatment guidelines, its adoption will likely continue.
• Long-Term HIV Management: The trend towards lifelong HIV treatment means a sustained demand for effective and well-tolerated regimens like BIKTARVY.
• Potential Label Expansions: While currently indicated for adult HIV-1 treatment, ongoing research could explore BIKTARVY's utility in specific sub-populations or as part of other HIV management strategies.
• Emerging Markets: Continued penetration into emerging markets with growing HIV populations and improving healthcare infrastructure presents significant growth potential.

Key Challenges:

• Patent Expiration and Generic Competition: The primary challenge is the eventual expiry of key patents, particularly the composition of matter patent for bictegravir in 2032. This opens the door for generic manufacturers to introduce lower-cost alternatives, which will inevitably erode BIKTARVY's market share and pricing power.
• Development of New Therapies: The pipeline for HIV treatment is active, with ongoing research into novel drug classes, long-acting injectables, and potential cure strategies. Breakthroughs in these areas could disrupt the market for existing oral STRs.
• Pricing Pressures: Increasing scrutiny on drug pricing from governments, payers, and the public may lead to greater pressure on BIKTARVY's pricing, especially as it matures in its lifecycle.
• Switching Incentives: Competitors may offer aggressive pricing or formulary incentives to encourage switches from BIKTARVY to their products.

What is the Projected Financial Trajectory for BIKTARVY?

BIKTARVY's financial trajectory is characterized by strong current performance with anticipated deceleration as patent expiries approach.

Sales Projections:

• Short to Medium Term (2024-2028): Continued strong sales growth is projected, driven by its established market position, ongoing clinical utility, and expansion in various markets. Analysts anticipate BIKTARVY's annual sales to remain at or near peak levels during this period, potentially exceeding $8 billion annually.
• Long Term (2029 onwards): Sales are expected to experience a decline as patent protections weaken and generic versions of bictegravir and the combination become available. The pace of this decline will depend on the timing of generic entry, the pricing of generics, and the availability of newer treatment modalities. Post-2032, sales are expected to decrease substantially.

Strategic Implications for Gilead Sciences:

Gilead's strategy will involve maximizing BIKTARVY's revenue during its period of market exclusivity while concurrently investing in the development of next-generation HIV therapies and diversifying its product portfolio to offset the eventual loss of exclusivity revenue from BIKTARVY.

Key Takeaways

BIKTARVY is a highly successful HIV treatment with robust current sales driven by its clinical advantages and broad market adoption. Its patent protection is robust, with key composition of matter patents extending to 2032, providing a significant period of market exclusivity. However, the impending patent expiries represent the most substantial future challenge, signaling an inevitable decline in revenue due to generic competition. Gilead Sciences' financial future will depend on its ability to leverage BIKTARVY's peak earnings and effectively transition to its next wave of innovative therapies.

Frequently Asked Questions

1. When is the earliest BIKTARVY could face generic competition in the U.S.?

Generic competition in the U.S. is primarily dictated by the expiry of key patents and the resolution of any patent litigation. The primary composition of matter patent for bictegravir is set to expire in 2032. However, generic manufacturers may attempt to challenge existing patents or launch authorized generics earlier.

2. How does BIKTARVY's renal and bone safety profile compare to older tenofovir formulations?

BIKTARVY's inclusion of tenofovir alafenamide (TAF) offers a distinct advantage over regimens containing tenofovir disoproxil fumarate (TDF). TAF is associated with significantly lower rates of renal and bone-related adverse events due to its more efficient delivery to target cells and lower circulating levels of tenofovir, reducing systemic exposure [3].

3. What is the typical patient population that BIKTARVY is prescribed for?

BIKTARVY is prescribed for adult patients with human immunodeficiency virus type 1 (HIV-1) infection. This includes both treatment-naïve individuals (those who have not previously received HIV therapy) and treatment-experienced individuals (those who have previously taken HIV medication), including patients with certain resistance mutations to other antiretroviral drugs.

4. What is the role of integrase inhibitors (INSTIs) in HIV treatment, and how does bictegravir fit within this class?

Integrase inhibitors (INSTIs) are a class of antiretroviral medications that work by blocking the action of HIV integrase, an enzyme essential for the virus to insert its genetic material into host cells. Bictegravir is a second-generation INSTI known for its high potency, favorable resistance profile, and good tolerability, making it a preferred choice in many first-line HIV regimens.

5. What is Gilead Sciences' strategy for managing revenue post-BIKTARVY patent expiry?

Gilead Sciences is actively investing in research and development for new HIV therapies, including long-acting injectables and potential cure-oriented strategies. The company also aims to diversify its oncology and inflammation portfolios to mitigate the impact of eventual revenue decline from its established HIV franchise, including BIKTARVY.

---

Cited Sources

[1] Sax, P. E., Wohl, D., Hung, C.-C., Laethem, L. V., deJesus, E., Saag, M., Gallant, J. E., Nguyen, T. T., Thompson, M., Brachman, C., Jones, M., Sklar, P., Elston, R. C., & Ruane, P. J. (2017). Bictegravir versus dolutegravir, each combined with emtricitabine and tenofovir alafenamide, for initial HIV-1 treatment: a phase 3, double-blind, randomised non-inferiority trials. The Lancet, 390(10089), 24–34. doi:10.1016/S0140-6736(17)30923-1

[2] White, N. C., & Johnson, V. A. (2017). HIV-1 Integrase Strand Transfer Inhibitors: An Emerging Class of Antiretroviral Agents. Pharmacotherapy, 37(10), 1323–1336. doi:10.1002/phar.2023

[3] Sax, P. E., Wohl, D., Yin, M.-T., Post, F., DeJesus, E., Saag, M., Bennett, K., Small, C., Gould, E. D., Fontes, L., Jenkins, J., Das, M., & Ruane, P. J. (2015). Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomized, double-blind, phase 3, non-inferiority trials. The Lancet, 385(9986), 2606–2615. doi:10.1016/S0140-6736(15)60517-4

[4] U.S. Patent No. 8,916,571. (2015). Bictegravir and uses thereof.

[5] U.S. Food and Drug Administration. (n.d.). Orphan Drug Act. Retrieved from https://www.fda.gov/for-industry/center-drug-evaluation-and-research-cder/orphan-drug-act

[6] Gilead Sciences, Inc. (2023). 2022 Annual Report on Form 10-K. Retrieved from https://www.sec.gov/ix?doc=/Archives/edgar/data/1081774/000108177423000012/gild-20221231.htm

[7] Gilead Sciences, Inc. (2024). Fourth Quarter and Full Year 2023 Results. Retrieved from https://investors.gilead.com/static-files/692927c3-d1c0-493a-b73d-92a1c36a001c